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journa l homepage : www.e lsev ie r . com/ loca te / rmedLETTER TO THE EDITOROn comparing different devices of inhalation productsDear Editor,
I read with interest the article by van Noord et al.1 to see
how the difficult task of inhalation product comparison had
been addressed. The authors investigated non-inferiority
versus the existing reference product and concluded that
Tiotropium 5 mg SMI is comparable with Tiotropium 18 mg HH
in terms of efficacy, pharmacokinetic and safety. In
contrast to the authors’ opinion, I think that the data
presented by the authors show that Tiotropium 5 mg SMI is
superior in lung deposition and efficacy, inferior in safety
and not comparable to Tiotropium 18 mg HH.
Firstly, the study was insensitive to compare devices
because Tiotropium 10 mg SMI provided an additional
0.001 L improvement in the primary efficacy variable
(trough FEV1) compared with the improvement observed
with Tiotropium 5 mg SMI over placebo (0.126 L). It means
that doubling the dose (100% increase) produces only
a 0.8% increase in response. This illustrates that 5 and 10 mg
of SMI were on the flat part of the doseeresponse curve.
Then, any dose would have looked similar. Obviously, this is
not demonstration of similarity; this is simply demonstra-
tion of an insensitive study design that is unable to
distinguish between two adjacent doses. In this respect, I
would like to highlight once more2,3 that it is essential to
learn that to be methodologically valid any comparison
between inhalation devices has to be done as a comparison
of the doseeresponse curves of both devices4,5 by means of
the calculation of the relative potency6e8 in a patient
population and study design able to show differences
between adjacent doses. Interestingly, despite the insen-
sitivity of the trial the difference between Tiotropium 5 mg
SMI and 18 mg HH (0.029 L) was statistically significant (the
95%CI of the difference does not include the zero value in
table 2a).
Secondly, the pharmacokinetic results based on urinary
data were able to show a much better sensitivity since
doubling the dose produced double systemic exposure,
which illustrates the usefulness of pharmacokinetic
comparisons. The amount excreted in urine reflects the
amount of drug deposited in the lungs since the fractionDOI of original article: 10.1016/j.rmed.2008.10.002.
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doi:10.1016/j.rmed.2009.02.017absorbed through the gastrointestinal tract is negligible for
Tiotropium. Therefore, the urinary data is able to confirm
what we already knew: a product with the same formula-
tion and device but with double strength should show
double lung deposition. However, the pharmacodynamic
endpoint was unable to provide any information on such
a simple comparison. Plasma systemic exposure is more
informative that urinary excretion data. Unfortunately, the
blood sampling times in these studies (0, 10, 60 and 360 min
after dosing) were clearly insufficient to obtain a reliable
estimate of the concentration - time profile. The plasma
concentration-time profile does not only provide informa-
tion about the lung deposition when the gastrointestinal
absorption is negligible, but also provide information on the
pattern of deposition, since the deeper the deposition the
shorter tmax and the higher Cmax.
9e11 From a pharmacoki-
netic point of view a 26% difference in urinary excretion is
not demonstrative of equivalence or bioequivalence. On
the contrary, it suggests that a 4-mg dose of SMI should be
compared with 18 mg of HH. With respect to safety, on one
side this study was not powered to compare the safety
profile. Therefore, the inability to detect differences in the
safety profile cannot be considered as demonstration of
similarity. The inability to reject the null hypothesis does
not support the validity of the null hypothesis. On the other
side, the systemic exposure with Tiotropium 5 mg SMI was
higher than with Tiotropium 18 mg HH. Therefore, it has to
be assumed that Tiotropium 5 mg SMI posses a worse
systemic safety profile, even if this small study was not able
to detect it.
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